ship head differ direct
reiter op
increas target price lower target price
stock struggl stock soar
differ stori far ytd
see recent move continu
start see beat rais period keytruda roll-out
continu especi line non-smal cell lung cancer nsclc
period uncertainti humira biosimilar prepar
enter eu market mid-octob friday compani beat
consensu ep estim cent updat
model compani rais target price
lower target price reiter
outperform rate continu see top pick
coverag maintain under-perform pleas let us
know would like updat model either compani
solid set stage even stronger
sinc data present mid-april
done impress job gain share keytruda nsclc
product captur new patient start nsclc
exclud egfr/alk patient share point increas
expect share continu increas go forward
expect increas patient base product drive upsid
keytruda estim rest year bridion
anim import driver quarter januvia
continu hold better expect look compani
execut busi develop opportun help bring growth
driver compani comfort keytruda
continu drive stori
estim guidanc rais limit also beat
estim quarter rais ep guidanc although lower
sale guidanc given impact currenc
surprisingli earn call provid mani new specif detail
manag plan defend humira biosimilar europ
assum minimum on-going investor uncertainti limit
potenti upsid stock come month also wait see
potenti chang us drug price may impact humira sale
us come year ahead us biosimilar entri
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
model updat thought speak
compani second opinion
estim guidanc rais limit also beat
estim quarter rais ep guidanc although lower
sale guidanc given impact currenc
surprisingli earn call provid mani new specif detail
manag plan defend humira biosimilar europ
assum minimum on-going investor uncertainti limit potenti
upsid stock come month also wait see potenti
chang us drug price may impact humira sale us come
year ahead us biosimilar entri see risk consensu
estim key pipelin product upadacitinib risankizumab also
wonder inclus warn around suicid ideat
mood disord packag insert may impact uptak orilissa
make minor model adjust base quarter lower
humira project concomit opex come year
valuat lower target price maintain
under-perform rate base concern around impact humira
biosimilar eu chang us drug price system might
impact domest sale target price base dcf
rel valuat earn blue sky valuat
grey sky valuat ep estim
chang pleas let us know
would like updat compani model
risk primari risk rate target price includ
success commerci pipelin execut along investor
focus near-term growth dividend oppos
valuat metric
number share
price month
 close
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
price jul rate under-perform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
opportun speak member team follow
confer call gain addit clariti dynam around certain product
well bake updat expect around fy
summar compani answer question
humira sale indic similar seen prior quarter
ex-u market will/wil face biosimilar competit
broken sale market
fair say ex-u sale face biosimilar disclos
eu market pretti matur market
eu major market matur
differ variou biosimilar product eu one best
consid proxi
self-inject better proxi hospit infus
use market market build peopl ground
chang impact co-pay accumul
minor line expect
exact date biosimilar entri eu
settl
receiv unspecifi royalti disclos book
suicid warn surpris impact
awar
broken
ex-u market canada
develop elsewher ex-u given price concern
ankylos spondyl failur phase
familiar result
one current indic go
model potenti cannib imbruvica
product much complimentari imbruvica competit
venclexta younger fit patient would typic get fcr
imbruvica popul cant toler potent treatment
assum gener follow us
us million unless otherwis state
sale
net interest incom
us million unless otherwis state
fx impact sale
us million unless otherwis state
product sold ex-amort
tax earn
average share outstand
dilut ep oper
us million unless otherwis state
rova-t acquir stemcentrx
pipelin total sale
model updat thought speak
compani second opinion
solid set stage even stronger
sinc data present mid-april
done impress job gain share keytruda nsclc
product captur new patient start nsclc exclud
egfr/alk patient share point increas
expect share continu increas go forward expect
increas patient base product drive upsid keytruda estim
rest year look execut
busi develop opportun help bring growth driver
compani comfort keytruda drive stori
notabl model updat given strong keytruda new patient start
increas global forecast keytruda us
us
also increas near-term sale forecast zepati nuvar although
fade soon offset increas lower forecast
zetia/vytorin remicad gardasil overal increas
revenu lower gm bp
follow modest adjust model expect ep
maintain out-performance rais pt target price
increas base dcf rel valuat
ep blue sky valuat grey sky valuat
reiter outperform rate expect number go
keytruda driven market leadership strong uptak nsclc
risk primari risk view poor execut
commerci opportun keytruda and/or disappoint clinic data
pleas let us know would like updat compani model
valuat metric
number share
price month
 close
merck co inc global health care compani deliv health
solut prescript medicin market
joint ventur oper segment
anim health consum allianc
price jul rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
keytruda januvia gardasil compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
keytruda januvia gardasil compar current base case
assumpt also model lower gross margin oper
margin base assumpt grey sky valuat base
dcf driven wacc termin valu
 close
follow-up manag
opportun speak member team follow
confer call gain addit clariti dynam around certain product
well expect around fy beyond
summar compani answer question
merck continu confid near long term growth prospect
keytruda driven continu penetr approv indic particularli
nsclc potenti indic includ breast gastric hepatocellular renal
head neck well adjuv stage cancer
merck note registr keytruda combin studi rcc
doesnt keytruda monotherapi arm studi keytruda
monotherapi rcc may suffici satisfi concern chmp
regard contribut variou compon combin therapi
receiv neg opinion chmp indic opdivo yervoy
us
us keytruda remain lead io therapi new patient start look
us sale benefit rapid adopt keytruda metastat nsclc
well growth bladder msi-high cancer
sinc april data set present share
keytruda nsclc exclud egfr/alk gone share point
keytruda current captur new patient start nsclc exclud
egfr/alk merck expect continu substanti adopt indic
beyond
compani believ data squamou nsclc pois
keytruda standard-of-car popul posit overal surviv
data keytruda cover
us sale quarter
came nsclc
melanoma
bladder
high cancer
rest indic
potenti approv
hepatocellular carcinoma pdufa date novemb
keytruda chemo non-squam nsclc pdufa septemb
keytruda chemo squamou nsclc pdufa date octob
adjuv melanoma pdufa februari
outsid us
ou sale repres total keytruda sale strong uptak nsclc
sale also continu grow melanoma head neck bladder cancer
nsclc monotherapi major revenu outsid us follow melanoma
tumor type merck alreadi major market
reimburs lung monotherapi combin therapi repres
addit signific opportun ou growth go forward
keytruda approv china melanoma first approv china
indic
us sale lynparza benefit continu growth ovarian cancer well
strong launch new breast cancer indic
ex-u sale benefit launch ovarian cancer japan go
forward manag expect recent breast cancer approv japan
expect ovarian cancer approv china continu enabl strong
us sale rep start promot lenvima renal cancer june
approv hepatocellular carcinoma pdufa august help
next month merck expect promot lenvima mani key countri
europ asia pacif
merck believ opportun gardasil short term long term growth
remain signific
merck continu see strong underli demand gardasil us
transit two-dos regimen us nearli complet gardasil start
see growth compani final two-dos transit
us merck point opportun increas vaccin rate
old also also believ
indic could import growth driver us pdufa octob
ex-u new geographi drive growth go forward
uptak china continu strong larger merck
initi expect compani still tri understand level demand
countri much product would need get countri
new data introduc countri like australia lot talk
elimin campaign market around world
pneumococc conjug vaccin current phase trial
vaccin prevent primari cmv infect healthi seroneg
women current larg phase ii studi
diabet franchis continu rel stabl strong januvia growth
ex-u market larg off-set continu price pressur
price pressur merck expect see
price pressur
good news ex-u strong growth compani middl
launch china help off-set price pressur
compani expect see
merck recent launch bridion china believ growth prospect us
ex-u remain strong
manag continu believ anim health key pillar compani
long-term growth strategi diversif particularli keytruda
also global scale synergi share human health busi
manag believ synergi two busi drive
above-industri growth anim health experienc exampl compani
protein vaccin technolog share across portfolio anim health also
access human health catalog led innov anim health
side current anim health investig oncolog diabet
companion anim busi addit intern invest anim health
also augment pipelin though busi develop
merck continu augment anim human health pipelin
intern invest well extern busi develop
anim health sale growth exclud impact fx
anim segment profit growth vs
exclud fx margin
next sever year merck continu see above-market growth anim
basi new product well strength in-lin product
long term manag continu expect oper leverag time
also want make sure make appropri invest long term
doesnt expect see margin expans get bolu spend
next year
near-term period meaning invest on-going
clinic studi keytruda well clinic studi lynparza lenvima
recent start drive lot growth
advanc sever program vaccin portfolio also drive spend
go merck expect gross margin declin slightli y/i due
expect larger neg manufactur varianc part
carryov effect cyberattack part due amort
go forward compani expect see margin expans due growth
product keytruda bridion new product current
margin benefit product off-set zetia
high margin compani also expect declin sale zepati due
competit mavyret also impact margin look forward whether
compani slightli higher margin slightli lower margin depend product
mix fx
busi develop remain import prioriti compani
compani activ look includ structur acquisit partnership
collabor licens
manag point dearth across industri recent believ
result ampl capit small biotech flow ipo creat
less need desir sell current deal get done high price
premium
proquad m-m-r ii varivax
sale
share
acquisition- divestiture-rel cost
aggreg charg relat format collabor eisai
charg viralyt acquisit
net decreas increas pbt
decreas increas net incom
revenu
amort intang
equiti incom affili
total incom expens
provis incom tax
proquad m-m-r ii varivax
primari women
hospit specialti
compani mention price
